Navigation Links
Mylan Appoints Rajiv Malik as Executive Vice President, Head of Global Technical Operations
Date:10/2/2007

PITTSBURGH, Oct. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced the appointment of Rajiv Malik as Executive Vice President in charge of Global Technical Operations. Mr. Malik has served in a similar capacity for Mylan since the Company acquired a controlling stake in Matrix Laboratories Limited (Matrix), where he is Chief Executive Officer, in January 2007.

As Head of Global Technical Operations, Mr. Malik will oversee the Company's global research and development (R&D) centers and manufacturing and distribution units, with responsibility for enhancing and rationalizing Mylan's global supply chain and expanded product pipeline, as well as leveraging Matrix, one of the world's largest suppliers of active pharmaceutical ingredients, across the enlarged company.

Mr. Malik has worked more than 24 years in the global generic pharmaceutical industry. In addition to his role at Mylan, Mr. Malik currently serves as Managing Director and Chief Executive Officer of Matrix. Prior to joining Matrix in 2005, he was Head of Global Development and Regulatory at Sandoz. He started his career in R&D at Ranbaxy Laboratories, rising to Head of Generics R&D.

Mylan's Vice Chairman and CEO Robert J. Coury commented, "Rajiv has been an invaluable addition to the Mylan management team since joining us in January. Since the close of the Matrix transaction, he has truly proven his capabilities and has been instrumental in the successful integration of Matrix. Rajiv has built an outstanding operational infrastructure that will allow us to capitalize on the efficiencies, synergies and sourcing opportunities we see from bringing together all three companies."

Mr. Malik earned his master's degree in pharmaceutical technology from Punjab University and has more than 60 process patents to his credit.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. Where Burnt Out Executives De-stress in Natures Lap
5. Asian Business Executives Urged to Be Eco-friendly
6. BMA Welcomes Scottish Executives Move to Raise the Purchase Age of Cigarettes
7. Skin Cancer Research To Go Global
8. Dementia - a global problem
9. Obesity a global problem
10. Suggestions to reduce global heart disease burden
11. Drop in global deaths from measles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... For over twenty-four years, Doctors on Liens ... personal injury victims find high quality medical care. When the company started in 1997, ... Fast forward to present day and the now ten-page directory features a vast array of ...
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to host ... other developmental disabilities. The group, which is being launched with the help of Robbie ... share stories and advice, seek help, and continue their education on how to best ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s ... ostomy patients, standing as living proof that attitude and determination can combine into ... issues that spike around the holidays. This campaign will offer patients a new-found ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that measures ... on the market can deliver all that rejiva can. , “Rejiva promotes relaxation and ... than the usual heart rate and steps taken”, adds Evens Augustin, CEO of Rijuven. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), ... Specialties, Inc. ("PSI").  The combination of Texas ... -based PSI bring together both company,s clinical expertise and ... payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... MARLBOROUGH, Mass. , Dec. 2, 2016 ... announced a definitive agreement to acquire certain manufacturing assets ... NVCN ) (TSX: NVC) advanced biological tissue business, as ... a total of $75 million in cash. The Neovasc ... heart valves, including the Boston Scientific Lotus™ Valve System. ...
(Date:12/2/2016)... MONMOUTH JUNCTION, N.J. , Dec. 2, 2016 /PRNewswire/ ... critical care immunotherapy leader commercializing its European Union approved ... in critically-ill and cardiac surgery patients worldwide, announced that ... present at the 9th Annual LD Micro Main ... 8 th , 2016 at the Luxe Sunset Boulevard ...
Breaking Medicine Technology: